ZyVersa Therapeutics (ZVSA) Projected to Post Quarterly Earnings on Monday

ZyVersa Therapeutics (NASDAQ:ZVSA) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect ZyVersa Therapeutics to post earnings of ($6.30) per share for the quarter.

ZyVersa Therapeutics Stock Performance

ZVSA opened at $0.75 on Friday. The business has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.52. ZyVersa Therapeutics has a 1 year low of $0.70 and a 1 year high of $8.40.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.